Feature | Drug-Eluting Balloons | October 22, 2015

Scoring Balloon Plus Drug-Coated Balloon Proves Effective for Drug-Eluting Stent Restenosis

Results of the ISAR-DESIRE 4 trial, presented at TCT 2015, show improved plaque modification versus DCB alone

ISAR-DESIRE 4 trial, TCT 2015, drug-coated balloon, DCB, scoring balloon, SCB, drug-eluting stent restenosis

Image courtesy of Medtronic

October 22, 2015 — Results from the ISAR-DESIRE 4 trial indicate that use of a scoring balloon plus a paclitaxel-coated balloon (PCB) was angiographically superior to a paclitaxel-coated balloon alone for the treatment of restenosis within limus-eluting stents.

Findings from the study were presented last week at the 27th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

Restenosis after drug-eluting stent implantation (DES) in patients with coronary artery disease occurs in up to 5-10 percent of cases, and the most appropriate treatment strategy remains unclear. Drug-coated balloons (DCB) are novel devices that can effectively treat in-stent restenosis. Scoring balloon (SCB) devices prevent balloon slippage and enhance local plaque disruption during angioplasty but have failed to demonstrate an advantage when used as stand-alone therapy. As an adjunct to DCB, scoring balloon pre-dilatation might enhance tissue uptake and improve clinical outcomes. ISAR-DESIRE 4 examined if the addition of a scoring balloon would lead to better results.

A prospective, randomized, active controlled, multicenter clinical trial, ISAR-DESIRE 4 enrolled 252 patients with limus-eluting stent restenosis and signs of ischemia. Patients were randomized 1:1 to a scoring balloon plus paclitaxel-coated balloon (N=125) or standard balloon plus paclitaxel-coated balloon (N=127) during angioplasty. Angiographic follow-up at six to eight months was performed in 80.4 percent of patients (N=203) and clinical follow-up occurred at 12 months.

The primary endpoint was the percent diameter stenosis at follow-up angiography. The results were 40.4 percent ± 21.4 for the SCB plus PCB group vs. 35 percent ± 16.8 for the PCB-alone group (p=0.047). The secondary endpoint of binary restenosis was also lower in SCB plus PCB compared to PCB alone (18.5 percent vs. 32 percent, P=0.03). The rates of target lesion revascularization (16.8 percent vs. 22.6 percent, P=0.25) and death/myocardial infarction (3.4 percent vs. 3.3 percent, P>0.99) were similar for both groups. 

“In patients with limus-eluting stent in-stent restenosis, plaque modification with SCB plus PCB was angiographically superior to standard PCB therapy in terms of in-segment percent diameter stenosis after six to eight month follow-up,” said investigator Robert A. Byrne, MB, B.Ch., Ph.D. from Deutsches Herzzentrum in Munich, Germany.

“Even though the rate of binary restenosis was lower with SCB plus PCB, clinical outcomes at one year were similar for both groups.”

The ISAR-DESIRE 4 trial was supported in part by a research grant from Biotronik AG. Byrne reported receiving lecture fees from B. Braun Melsungen AG, Biotronik and Boston Scientific.

For more information: www.tctconference.com

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init